Overview

The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid Treatment

Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
0
Participant gender:
All
Summary
The efficacy of risedronate in prevention of bone loss in patients receiving high dose corticosteroid treatment
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Tuen Mun Hospital
Treatments:
Etidronic Acid
Risedronate Sodium
Risedronic Acid
Criteria
Inclusion Criteria:

1. Patients with various medical conditions who require high dose glucocorticoid
treatment: (1) pulse methylprednisolone; (2) oral prednisolone (>=0.8mg/kg/day) or
equivalent for at least 6 weeks.

2. Age>=18 years and <75 years.

Exclusion Criteria:

1. Pregnant or lactating women.

2. Uncorrected hypocalcemia.

3. History of esophageal stricture.

4. Previous intolerance or hypersenstivity to biphosphonates.